<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Toxic erythema of chemotherapy (hand-foot syndrome)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Toxic erythema of chemotherapy (hand-foot syndrome)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Toxic erythema of chemotherapy (hand-foot syndrome)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cuong V Nguyen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lida Zheng, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H984975377"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term "toxic erythema of chemotherapy" (TEC) was proposed in 2008 as a unifying, descriptive, diagnostic entity for the various clinical and histopathologic reaction patterns with significant overlapping features reported with chemotherapy [<a href="#rid1">1</a>]. The clinical presentation most frequently seen involves the hands and feet, hence the name "hand-foot syndrome" (HFS), which has been known by a variety of terms including acral erythema, palmar-plantar erythrodysesthesia, palmar-plantar erythema, toxic acral erythema, toxic erythema of the palms and soles, Burgdorf's reaction, and periarticular thenar erythema with onycholysis (PATEO) syndrome [<a href="#rid2">2</a>].</p><p>Originally reported in patients receiving high-dose <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> for acute leukemia, HFS has been frequently described in patients receiving <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (an oral fluoropyrimidine that is converted in vivo to <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, providing prolonged tissue exposure), or fluorouracil, although many other drugs have been implicated  (<a class="graphic graphic_table graphicRef78089" href="/d/graphic/78089.html" rel="external">table 1</a>) [<a href="#rid2">2-7</a>].</p><p>Multitargeted tyrosine kinase inhibitors, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, and other kinase inhibitors that target angiogenesis, are associated with a high incidence of a hand-foot skin reaction, but the clinical and histologic patterns differ from the classic HFS that develops with conventional cytotoxic agents. Hand-foot skin reaction is discussed in detail elsewhere. Other adverse effects of conventional chemotherapeutic agents are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/103060.html" rel="external">"Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p></p><p class="headingAnchor" id="H2803568072"><span class="h1">FREQUENCY AND CAUSATIVE AGENTS</span><span class="headingEndMark"> — </span>TEC occurs in approximately 6 to over 60 percent of patients treated with the chemotherapeutic agents most frequently implicated (eg, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, fluoropyrimidines [<a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>], <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>); frequency varies depending on the specific agent, dose, and mode of administration [<a href="#rid2">2,8,9</a>]. However, TEC may occur with many other drugs  (<a class="graphic graphic_table graphicRef78089" href="/d/graphic/78089.html" rel="external">table 1</a>). At least in the case of cytarabine, capecitabine, and doxorubicin, TEC is dose related. Drug formulations and administration schedules that result in sustained serum levels over time are more frequently associated with TEC.</p><p>As an example, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> is associated with a higher frequency of TEC than the nonencapsulated form of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, particularly with initial doses greater than 40 mg/m<sup>2</sup> [<a href="#rid10">10</a>]. TEC is often the dose-limiting toxicity with certain chemotherapeutic agents (eg, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>) [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H2669819593"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of TEC is not well understood. A direct toxic effect of the chemotherapeutic agent on eccrine coils (which are in highest density on the palms and soles) has been proposed. However, there is no direct evidence to support this theory as microscopic evidence of damage to the eccrine sweat glands or ducts is only infrequently reported [<a href="#rid12">12,13</a>].</p><p>TEC most often develops in patients who have neither undergone hematopoietic cell transplantation nor received blood products [<a href="#rid14">14</a>]. Finally, the occasional co-occurrence of facial erythema/edema, papular rash, and fever has led some to view this as a type I (immunoglobulin E [IgE]-mediated) allergic reaction, though TEC is often delayed by two to three weeks following chemotherapy rather than within 24 hours (as is usually seen with type I reactions) [<a href="#rid15">15</a>].</p><p>For patients treated with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, at least some data suggest that expression of the capecitabine-activating enzyme thymidine phosphorylase (TYMP) is significantly greater in the skin of the palms compared with skin on the lower back, providing higher tissue levels of the active moiety to this area [<a href="#rid16">16</a>]. Furthermore, the proliferative rate of epidermal basal cells in the palm was also higher compared with skin from the back, suggesting that palmar skin might be more sensitive to the local action of cytotoxic drugs.</p><p>Fluoropyrimidine toxicity may be associated with genetic polymorphisms of dihydropyrimidine dehydrogenase (<em>DPYD</em>) and thymidylate synthase (<em>TYMS</em>), genes that encode for two enzymes that are involved in metabolism [<a href="#rid17">17</a>]. Although genetic tests are available that sequence the entire <em>DPYD</em> gene and identify some <em>TYMS</em> polymorphisms that predispose to excess hematologic and gastrointestinal toxicity, genetic testing is not considered standard of care prior to initiating fluoropyrimidine therapy (at least in North America). (See  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Testing for DPYD and TYMS variants'</a>.)</p><p class="headingAnchor" id="H2559963506"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H2870705994"><span class="h2">Timing</span><span class="headingEndMark"> — </span>Symptoms of TEC often develop one to three weeks after chemotherapy administration but may occur sooner, often within five to seven days with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>.</p><p class="headingAnchor" id="H2713607105"><span class="h2">Hand-foot syndrome</span><span class="headingEndMark"> — </span>When TEC affects the hands and feet (HFS), it is often most pronounced over the fat pads of the proximal phalanges  (<a class="graphic graphic_picture graphicRef77501 graphicRef79857" href="/d/graphic/77501.html" rel="external">picture 1A-B</a>). Most cases are of grade 1 or grade 2 severity  (<a class="graphic graphic_table graphicRef73474" href="/d/graphic/73474.html" rel="external">table 2</a>) [<a href="#rid9">9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– Affected patients initially complain of a tingling sensation, which is followed by the development of edema and tender, symmetric erythema. Skip areas may occur as can extension to the dorsal surfaces of the extremities. Affected areas may develop pallor, blistering, and desquamation [<a href="#rid18">18-20</a>]. Cutaneous and oral hyperpigmentation have been described in patients with darkly pigmented skin who have capecitabine-associated HFS [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on quality of life</strong> – HFS is a painful condition and may limit daily activities such as walking or grasping objects. Functional impairment is a component of the grading system for severity of HFS  (<a class="graphic graphic_table graphicRef73474" href="/d/graphic/73474.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course </strong>– HFS is dose related and usually resolves within two to four weeks after discontinuation of the causative agent.</p><p></p><p class="headingAnchor" id="H920529060"><span class="h2">Clinical variants</span><span class="headingEndMark"> — </span>Variants of TEC include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant intertrigo</strong> – TEC may also occur in intertriginous sites (previously known as malignant intertrigo) with involvement of the axillary folds, antecubital/popliteal fossae, neck, inguinal folds, buttocks, and genitals, mimicking a symmetric drug-related intertriginous and flexural exanthema [<a href="#rid23">23-25</a>]. Occasionally, it may be misdiagnosed as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption", section on 'Intertriginous and flexural reaction pattern'</a>.)</p><p></p><p class="bulletIndent1">Involvement of the ears is commonly seen with <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, giving rise to the phrase "Ara-C (cytarabine) ears."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PATEO syndrome</strong> – Periarticular thenar erythema with onycholysis (PATEO) syndrome, a variant of TEC, was originally described in 2003 as HFS associated with taxanes (<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>) that is accentuated over the dorsum of the hands (particularly the hypothenar eminence) or base of the thumb [<a href="#rid27">27-30</a>]. Distinct nail changes, including onycholysis, can occur due to cytotoxicity to the nail matrix. PATEO syndrome can additionally affect the skin around the Achilles tendon. (See  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents", section on 'Onycholysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fixed erythrodysesthesia plaque</strong> – Another presumed variant of TEC, termed "fixed erythrodysesthesia plaque," is characteristic of intravenous injections of <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid31">31-33</a>]. This lesion develops as a fixed, solitary, erythematous plaque proximal to the infusion site that does not involve the palms or soles. It usually resolves with desquamation, leaving an area of hyperpigmented skin five to six weeks later.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stevens-Johnson syndrome/toxic epidermal necrolysis-like presentation</strong> – A particularly severe bullous variant resembling SJS/TEN, progressing to full-thickness epidermal necrosis and sloughing, has been reported following <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> or high-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, particularly in children [<a href="#rid34">34-39</a>].</p><p></p><p class="headingAnchor" id="H1018200400"><span class="h2">Fingerprint loss</span><span class="headingEndMark"> — </span>One potential consequence of capecitabine-associated TEC is the loss of fingerprints [<a href="#rid40">40-43</a>]. Patients on long-term therapy should be advised of this potential adverse effect, since it may be an impediment in situations in which fingerprint identification is necessary (eg, international travel).</p><p>However, an important point is that fingerprint loss is not permanent. In a prospective cohort study of 66 patients who were undergoing treatment with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> or a tyrosine kinase inhibitor and who were fingerprinted at baseline, within 6 to 10 weeks after treatment initiation, and after treatment discontinuation, nine patients (14 percent) had severe loss of fingerprints [<a href="#rid43">43</a>]. Loss was unrelated to the severity of TEC in this study. Complete recovery of fingerprints occurred in all three patients who were able to participate in post-treatment assessments within two to four weeks after treatment discontinuation.</p><p class="headingAnchor" id="H162904261"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2637445084"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>The diagnosis of TEC is usually clinical, based on medication history and clinical presentation.</p><p class="headingAnchor" id="H2887057634"><span class="h2">Skin biopsy and histopathology</span><span class="headingEndMark"> — </span>A skin biopsy is not routinely performed in patients with TEC, as the histopathologic changes are generally nonspecific. A vacuolar interface dermatitis with basilar squamatization and necrotic keratinocytes is most commonly seen, with superficial dermal edema and a mild, perivascular lymphocytic infiltrate  (<a class="graphic graphic_picture graphicRef139730" href="/d/graphic/139730.html" rel="external">picture 2</a>) [<a href="#rid8">8,44</a>]. Epidermal dysmaturation resembling squamous cell carcinoma in situ may be observed  (<a class="graphic graphic_picture graphicRef139732" href="/d/graphic/139732.html" rel="external">picture 3</a>) [<a href="#rid45">45</a>]. Changes in the adnexal structures, including vacuolar changes in the epithelium, neutrophilic infiltration or necrosis of eccrine glands, or squamous syringometaplasia, have also been described  (<a class="graphic graphic_picture graphicRef139733" href="/d/graphic/139733.html" rel="external">picture 4</a>) [<a href="#rid46">46-49</a>].</p><p>The pathologic differential diagnosis includes acute graft-versus-host disease (in the appropriate clinical setting) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). The distinction of TEC from graft-versus-host disease and SJS/TEN is important since the treatments are distinct. Unfortunately, a biopsy may not be able to distinguish among these entities in a clinically relevant timeframe. (See  <a class="medical medical_review" href="/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Skin'</a> and  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3521337136"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The main treatment for TEC is drug interruption or dose modification, depending on the severity of the reaction, in combination with topical corticosteroids and supportive treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interruption/dose modification</strong> – For patients who develop severe (grade 2 or 3 [depending on the drug]  (<a class="graphic graphic_table graphicRef73474" href="/d/graphic/73474.html" rel="external">table 2</a>)) HFS, subsequent chemotherapy doses should be reduced to avoid recurrence. Based upon the severity of the reaction, the hazard of rechallenge, and the clinical situation, it may be necessary to discontinue therapy entirely and switch to an alternative regimen if one is available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical corticosteroids</strong> – We suggest super high-potency topical corticosteroids (group 1  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 3</a>)) for the treatment of severe HFS (grade 2 or 3) in combination with supportive treatment. Topical corticosteroids are applied twice daily to the involved areas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive treatments</strong> – Supportive treatment includes wound care for erosions and ulcerations, emollients and topical keratolytics for hyperkeratotic areas, and analgesics for pain control [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">A small, phase 2A trial (21 patients) found that topical heparin (1000 international units/g) applied four times daily to the hands and feet of patients with grade ≤2 capecitabine-induced HFS reduced HFS severity by at least 1 grade in 90 percent of patients, with a median response time of three weeks [<a href="#rid50">50</a>]. However, these findings need to be confirmed in larger studies.</p><p></p><p class="headingAnchor" id="H308224642"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>TEC usually resolves with superficial desquamation of involved areas within two to four weeks after discontinuation of the causative agent. There are usually no long-term sequelae, although palmoplantar keratoderma may develop as a result of longstanding HFS [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H2876340099"><span class="h1">PREVENTION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>urea</strong> – In patients who will be treated with fluoropyrimidines, the local application of a topical <a class="drug drug_general" data-topicid="10031" href="/d/drug information/10031.html" rel="external">urea</a> 10% cream may help prevent HFS. The urea-based cream is applied to hands and feet three times per day and should be reapplied after washing hands. At low concentrations (2% to 10%), topical urea acts as a humectant that increases the hydration of the stratum corneum and is generally well tolerated. Urea up to 30% acts as an emollient and keratolytic, with urea greater than 30% functioning mostly as a keratolytic. These higher concentrations can be useful in instances of chronic reactions that lead to skin thickening [<a href="#rid52">52</a>]. The prophylactic benefit of topical urea treatment has not been demonstrated for other chemotherapy agents. However, given the low risk for toxic effects, a therapeutic trial is reasonable for patients at risk of developing HFS with other drugs.</p><p></p><p class="bulletIndent1">The efficacy of topical <a class="drug drug_general" data-topicid="10031" href="/d/drug information/10031.html" rel="external">urea</a> with or without lactic acid for the prevention of HFS has been evaluated in a few randomized trials and meta-analyses with conflicting results. Moreover, as the included studies included a variety of interventions as comparators but not vehicle, the benefit of urea cream versus emollient cream remains uncertain:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2022 meta-analysis of four randomized trials found that prophylactic treatment with <a class="drug drug_general" data-topicid="10031" href="/d/drug information/10031.html" rel="external">urea</a> was associated with a reduced risk of developing grade 2 or higher HFS or hand-foot skin reaction (odds ratio [OR] 0.62, 95% CI 0.49-0.79). However, subgroup analysis of only HFS demonstrated reduced risk of all-grade HFS (OR 0.44, 95% CI 0.22-0.90) but not grade 2 or higher HFS (OR 0.78, 95% CI 0.29-2.09) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of three trials of prophylactic <a class="drug drug_general" data-topicid="10031" href="/d/drug information/10031.html" rel="external">urea</a> cream for capecitabine-induced HFS did not find it effective in reducing the risk of all-grade HFS (risk ratio [RR] 0.81, 95% CI 0.52-1.26) as well grade 2 or greater HFS (RR 0.74, 95% CI 0.41-1.32) [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>diclofenac</strong> – A randomized trial that included 263 patients with breast or gastrointestinal cancer undergoing <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> treatment evaluated the efficacy of topical <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> applied to the palms and dorsa of the hands twice daily in preventing HFS [<a href="#rid55">55</a>]. At 12 weeks, fewer patients in the topical diclofenac gel group developed grade 2 or higher HFS than those in the vehicle group (3.8 versus 15 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celecoxib</strong> – In a 2014 meta-analysis of randomized trials (140 patients), oral <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> 200 to 400 mg twice daily for 12 to 18 weeks significantly decreased the risk of all-grade and grade ≥2 HFS (OR 0.37, 95% CI 0.19-0.71; and OR 0.47, 95% CI 0.29-0.78, respectively) [<a href="#rid56">56</a>]. These results were confirmed in a 2022 meta-analysis [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">However, <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> is known for its potential cardiovascular adverse effects with long-term use and upper gastrointestinal risk of bleeding. In our view, the benefit-to-risk ratio is not favorable when considering the use of celecoxib for the prevention of HFS. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">Pyridoxine</a><strong> </strong>–<strong> </strong>Early studies suggesting symptomatic improvement from pyridoxine in patients with HFS led to interest in the use of this vitamin as a preventive agent [<a href="#rid57">57,58</a>]. However, in four separate phase 3 trials in which patients receiving capecitabine-based chemotherapy or <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> were randomly assigned to either pyridoxine (at a dose of 150 or 200 mg daily) or placebo, pyridoxine did not prevent this complication, lessen its severity, or permit higher doses of chemotherapy to be administered [<a href="#rid59">59-62</a>]. Whether higher daily doses of pyridoxine might confer greater protection against HFS is uncertain [<a href="#rid63">63,64</a>]. The results of three meta-analyses suggest that there is inadequate evidence to make any recommendation about using pyridoxine (at any dose) for the prevention of chemotherapy-induced HFS [<a href="#rid53">53,56,65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other treatments that have been used in a limited number of patients include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regional cooling (not indicated for drugs administered as continuous infusion) [<a href="#rid66">66,67</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Antiperspirants [<a href="#rid68">68</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Topical <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a> [<a href="#rid69">69</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Topical silymarin [<a href="#rid70">70</a>] and other herbal products [<a href="#rid71">71</a>]</p><p></p><p class="bulletIndent1">However, none of these treatments have been evaluated in high-quality studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of friction</strong> <strong>injuries</strong> – Patients should be counseled on avoidance of friction injuries to the hands and feet. For example, patients should avoid using a pumice stone for exfoliation of hyperkeratotic skin and should wear proper fitting shoes with socks.</p><p></p><p class="headingAnchor" id="H4113682579"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>–<strong> </strong>The term "toxic erythema of chemotherapy" (TEC) refers to various cytotoxic cutaneous reactions that can occur with conventional chemotherapy. The clinical presentation most frequently seen involves the hands and feet (hand-foot syndrome [HFS], also called palmar-plantar erythrodysesthesia or acral erythema). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causative agents</strong> – Drugs most frequently associated with TEC include <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, fluoropyrimidines (<a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>), <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>. However, TEC may occur with many other drugs  (<a class="graphic graphic_table graphicRef78089" href="/d/graphic/78089.html" rel="external">table 1</a>). (See <a class="local">'Frequency and causative agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hand-foot syndrome</strong> – Symptoms of HFS typically develop one to three weeks after chemotherapy administration. Affected patients initially complain of a tingling sensation, which is followed by edema and tender, symmetric erythema most pronounced over the fat pads of the distal phalanges  (<a class="graphic graphic_picture graphicRef79857 graphicRef77501" href="/d/graphic/79857.html" rel="external">picture 1A-B</a>). Transient fingerprint loss can occur in HFS associated with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>. HFS is dose related and usually resolves within two to four weeks after discontinuation of the causative agent. (See <a class="local">'Hand-foot syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical variants </strong>– Clinical variants include malignant intertrigo; periarticular thenar erythema with onycholysis (PATEO) syndrome associated with taxanes; fixed erythrodysesthesia plaque proximal to the infusion site, characteristic of intravenous <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>; and a severe bullous variant resembling Stevens-Johnson syndrome/toxic epidermal necrolysis. (See <a class="local">'Clinical variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of TEC is usually clinical. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The main treatment for TEC is drug interruption or dose modification, depending on the severity of the reaction  (<a class="graphic graphic_table graphicRef73474" href="/d/graphic/73474.html" rel="external">table 2</a>). For patients with severe HFS (grade 2 or 3), we suggest super high-potency topical corticosteroids (group 1  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 3</a>)), rather than other topical agents, in combination with supportive treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Supportive treatment includes wound care for erosions and ulcerations, emollients, topical keratolytics for hyperkeratotic areas, and oral analgesics for pain control. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – For patients undergoing treatment with fluoropyrimidines, we suggest topical <a class="drug drug_general" data-topicid="10031" href="/d/drug information/10031.html" rel="external">urea</a> preparations or topical <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> for the prevention of HFS (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The 2% to 10% urea-based cream is applied to the hands and feet three times per day and should be reapplied after washing hands. Topical diclofenac is applied to the hands and feet twice daily. Although oral <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> has been shown to be effective for the prevention of HFS, the associated risks of cardiovascular adverse effects and upper gastrointestinal bleeding make it an unsuitable prophylactic treatment. (See <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59:524.</a></li><li><a class="nounderline abstract_t">Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71:787.</a></li><li><a class="nounderline abstract_t">Hoff PM, Valero V, Ibrahim N, et al. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998; 82:965.</a></li><li><a class="nounderline abstract_t">Eich D, Scharffetter-Kochanek K, Eich HT, et al. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 2002; 25:599.</a></li><li><a class="nounderline abstract_t">Ozmen S, Dogru M, Bozkurt C, Kocaoglu AC. Probable cytarabine-induced acral erythema: report of 2 pediatric cases. J Pediatr Hematol Oncol 2013; 35:e11.</a></li><li><a class="nounderline abstract_t">Farr KP, Safwat A. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011; 4:229.</a></li><li><a class="nounderline abstract_t">Karol SE, Yang W, Smith C, et al. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. Cancer 2017; 123:3602.</a></li><li><a class="nounderline abstract_t">Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1:225.</a></li><li><a class="nounderline abstract_t">Huang J, Ye S, Feng S, et al. Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2023; 38:61.</a></li><li><a class="nounderline abstract_t">Kim RJ, Peterson G, Kulp B, et al. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 2005; 97:374.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097.</a></li><li><a class="nounderline abstract_t">Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24:457.</a></li><li><a class="nounderline abstract_t">Tsuboi H, Yonemoto K, Katsuoka K. A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature. J Dermatol 2005; 32:921.</a></li><li><a class="nounderline abstract_t">Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.</a></li><li class="breakAll">Weiss RB. Hypersensitivity reactions. In: The Chemotherapy Source Book, 3rd ed, Lippincott, Williams, and Wilkins, 2001. p.442.</li><li><a class="nounderline abstract_t">Milano G, Etienne-Grimaldi MC, Mari M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008; 66:88.</a></li><li><a class="nounderline abstract_t">Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031.</a></li><li><a class="nounderline abstract_t">Cohen PR. Acral erythema: a clinical review. Cutis 1993; 51:175.</a></li><li class="breakAll">Hood AF, Haynes HA. Dermatologic complications. In: Cancer Medicine, Holland JF, et al (Eds), Williams &amp; Wilkins,  p.3141.</li><li><a class="nounderline abstract_t">Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982; 97:61.</a></li><li><a class="nounderline abstract_t">Nascimento ADAD, Porto DM, Vidal AKL. Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome - A literature review. An Bras Dermatol 2023; 98:302.</a></li><li><a class="nounderline abstract_t">Whorton AE, Razzak AN, Jha P. Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient. Cureus 2022; 14:e26891.</a></li><li><a class="nounderline abstract_t">Sapp CM, DeSimone P. Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. Clin Colorectal Cancer 2007; 6:382.</a></li><li><a class="nounderline abstract_t">Smith SM, Milam PB, Fabbro SK, et al. Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Rep 2016; 2:476.</a></li><li><a class="nounderline abstract_t">Kurtzman DJ, Oulton J, Erickson C, Curiel-Lewandrowski C. Everolimus-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE). Dermatitis 2016; 27:76.</a></li><li><a class="nounderline abstract_t">Choate EA, Sarantopoulos GP, Worswick SD, Truong AK. Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap. Dermatol Online J 2020; 26.</a></li><li><a class="nounderline abstract_t">Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 2003; 26:435.</a></li><li><a class="nounderline abstract_t">Rodríguez-Lomba E, Molina-López I, Suárez-Fernández R, Baniandrés-Rodríguez O. Periarticular Thenar Erythema and Onycholysis Syndrome: A Manifestation of Taxane-Induced Cutaneous Toxicity. Actas Dermosifiliogr 2017; 108:595.</a></li><li><a class="nounderline abstract_t">Rzepecki AK, Franco L, McLellan BN. PATEO syndrome: periarticular thenar erythema with onycholysis. Acta Oncol 2018; 57:991.</a></li><li><a class="nounderline abstract_t">Ferreira O, Baudrier T, Mota A, et al. Docetaxel-induced acral erythema and nail changes distributed to photoexposed areas. Cutan Ocul Toxicol 2010; 29:296.</a></li><li><a class="nounderline abstract_t">Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009; 15:29.</a></li><li><a class="nounderline abstract_t">Chu CY, Yang CH, Yang CY, et al. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 2000; 142:808.</a></li><li><a class="nounderline abstract_t">Cutler L, Wang H, Kim G, Chiu M. Fixed erythrodysesthesia plaques at sites of intravenous docetaxel infusion: an unusual cutaneous reaction to chemotherapy. Int J Dermatol 2022; 61:e316.</a></li><li><a class="nounderline abstract_t">Hellier I, Bessis D, Sotto A, et al. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996; 132:590.</a></li><li><a class="nounderline abstract_t">Werchniak AE, Chaffee S, Dinulos JG. Methotrexate-induced bullous acral erythema in a child. J Am Acad Dermatol 2005; 52:S93.</a></li><li><a class="nounderline abstract_t">Ozkaya-Bayazit E, Diz-Küçükkaya R, Akasya E, et al. Bullous acral erythema and concomitant pigmentation on the face and occluded skin. J Eur Acad Dermatol Venereol 2000; 14:139.</a></li><li><a class="nounderline abstract_t">Azurdia RM, Clark RE, Friedmann PS. Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999; 24:64.</a></li><li><a class="nounderline abstract_t">Podjasek JO, Camilleri MJ. Bullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*. J Cutan Pathol 2012; 39:382.</a></li><li><a class="nounderline abstract_t">Aytaç S, Gümrük F, Cetin M, et al. Acral erythema with bullous formation: a side effect of chemotherapy in a child with acute lymphoblastic leukemia. Turk J Pediatr 2010; 52:211.</a></li><li><a class="nounderline abstract_t">Wong M, Choo SP, Tan EH. Travel warning with capecitabine. Ann Oncol 2009; 20:1281.</a></li><li><a class="nounderline abstract_t">Chavarri-Guerra Y, Soto-Perez-de-Celis E. Images in clinical medicine. Loss of fingerprints. N Engl J Med 2015; 372:e22.</a></li><li><a class="nounderline abstract_t">Al-Ahwal MS. Chemotherapy and fingerprint loss: beyond cosmetic. Oncologist 2012; 17:291.</a></li><li><a class="nounderline abstract_t">van Doorn L, Veelenturf S, Binkhorst L, et al. Capecitabine and the Risk of Fingerprint Loss. JAMA Oncol 2017; 3:122.</a></li><li><a class="nounderline abstract_t">Levine LE, Medenica MM, Lorincz AL, et al. Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 1985; 121:102.</a></li><li><a class="nounderline abstract_t">Chun YS, Chang SN, Oh D, Park WH. A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation. J Am Acad Dermatol 2000; 43:358.</a></li><li><a class="nounderline abstract_t">Brehler R, Reimann S, Bonsmann G, Metze D. Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Am J Dermatopathol 1997; 19:73.</a></li><li class="breakAll">Smoller BR, Horn TD. Chemotherapy-induced drug eruptions. In: Dermatopathology in Systemic Disease, Smoller BR, Horn TD (Eds), Oxford University Press, 2001. p.298.</li><li><a class="nounderline abstract_t">Valks R, Fraga J, Porras-Luque J, et al. Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol 1997; 133:873.</a></li><li><a class="nounderline abstract_t">Itamoto S, Imafuku K, Miyazawa H, et al. Hand-foot syndrome histopathologically presenting eccrine squamous syringometaplasia due to pembrolizumab after lenvatinib treatment. J Cutan Pathol 2023; 50:932.</a></li><li><a class="nounderline abstract_t">Rodríguez-Garzotto A, Iglesias-Docampo L, Díaz-García CV, et al. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies. Ther Adv Med Oncol 2022; 14:17588359221086911.</a></li><li><a class="nounderline abstract_t">Jucglà A, Sais G, Navarro M, Peyri J. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131:364.</a></li><li><a class="nounderline abstract_t">Piquero-Casals J, Morgado-Carrasco D, Granger C, et al. Urea in Dermatology: A Review of its Emollient, Moisturizing, Keratolytic, Skin Barrier Enhancing and Antimicrobial Properties. Dermatol Ther (Heidelb) 2021; 11:1905.</a></li><li><a class="nounderline abstract_t">Pandy JGP, Franco PIG, Li RK. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer 2022; 30:8655.</a></li><li><a class="nounderline abstract_t">Huang XZ, Chen Y, Chen WJ, et al. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. Int J Cancer 2018; 142:2567.</a></li><li><a class="nounderline abstract_t">Santhosh A, Batra A, Kumar A, et al. Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine. J Clin Oncol 2023; 41:12005.</a></li><li><a class="nounderline abstract_t">Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 2014; 22:1585.</a></li><li><a class="nounderline abstract_t">Vukelja SJ, Baker WJ, Burris HA 3rd, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85:1432.</a></li><li><a class="nounderline abstract_t">Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8:57.</a></li><li><a class="nounderline abstract_t">Kang YK, Lee SS, Yoon DH, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010; 28:3824.</a></li><li><a class="nounderline abstract_t">von Gruenigen V, Frasure H, Fusco N, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 2010; 116:4735.</a></li><li><a class="nounderline abstract_t">Corrie PG, Bulusu R, Wilson CB, et al. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer 2012; 107:585.</a></li><li><a class="nounderline abstract_t">Yap YS, Kwok LL, Syn N, et al. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. JAMA Oncol 2017; 3:1538.</a></li><li><a class="nounderline abstract_t">Fang XH, Wu Q, Han XM, et al. High dose pyridoxine for the prevention of hand-foot syndrome caused by capecitabine. Oncology 2010; 30:1081.</a></li><li><a class="nounderline abstract_t">Chalermchai T, Tantiphlachiva K, Suwanrusme H, et al. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia Pac J Clin Oncol 2010; 6:155.</a></li><li><a class="nounderline abstract_t">Chen M, Zhang L, Wang Q, Shen J. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. PLoS One 2013; 8:e72245.</a></li><li><a class="nounderline abstract_t">Mangili G, Petrone M, Gentile C, et al. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 2008; 108:332.</a></li><li><a class="nounderline abstract_t">Bun S, Yunokawa M, Tamaki Y, et al. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. Support Care Cancer 2018; 26:2161.</a></li><li><a class="nounderline abstract_t">Templeton AJ, Ribi K, Surber C, et al. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 2014; 23:244.</a></li><li><a class="nounderline abstract_t">Meadows KL, Rushing C, Honeycutt W, et al. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer 2015; 23:1311.</a></li><li><a class="nounderline abstract_t">Elyasi S, Shojaee FSR, Allahyari A, Karimi G. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Phytother Res 2017; 31:1323.</a></li><li><a class="nounderline abstract_t">Deng B, Sun W. Herbal medicine for hand-foot syndrome induced by fluoropyrimidines: A systematic review and meta-analysis. Phytother Res 2018; 32:1211.</a></li></ol></div><div id="topicVersionRevision">Topic 142102 Version 1.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18694683" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Toxic erythema of chemotherapy: a useful clinical term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795111" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486588" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hand-foot syndrome following prolonged infusion of high doses of vinorelbine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12478008" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22767133" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Probable cytarabine-induced acral erythema: report of 2 pediatric cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21537373" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28493546" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11702367" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36872385" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863132" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11689577" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2061446" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chemotherapy-induced acral erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361756" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071309" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mucocutaneous reactions to chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071309" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mucocutaneous reactions to chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18341672" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Candidate mechanisms for capecitabine-related hand-foot syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590654" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8444048" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acral erythema: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8444048" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acral erythema: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7046555" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36803558" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome - A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35978746" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17311704" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27981223" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26983097" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Everolimus-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32239890" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14528066" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cutaneous hand and foot toxicity associated with cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117052" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Periarticular Thenar Erythema and Onycholysis Syndrome: A Manifestation of Taxane-Induced Cutaneous Toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29283012" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : PATEO syndrome: periarticular thenar erythema with onycholysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20608863" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Docetaxel-induced acral erythema and nail changes distributed to photoexposed areas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753180" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cutaneous reaction associated with weekly docetaxel administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792238" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34351630" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fixed erythrodysesthesia plaques at sites of intravenous docetaxel infusion: an unusual cutaneous reaction to chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624164" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High-dose methotrexate-induced bullous variant of acral erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858519" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Methotrexate-induced bullous acral erythema in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972102" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bullous acral erythema and concomitant pigmentation on the face and occluded skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233654" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chemotherapy-induced acral erythema (CIAE) with bullous reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22335596" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20560263" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acral erythema with bullous formation: a side effect of chemotherapy in a child with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470576" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Travel warning with capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25875278" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Images in clinical medicine. Loss of fingerprints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22298801" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chemotherapy and fingerprint loss: beyond cosmetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27560202" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Capecitabine and the Risk of Fingerprint Loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3855356" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Distinctive acral erythema occurring during therapy for severe myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10901723" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9056658" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9056658" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236526" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37438151" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hand-foot syndrome histopathologically presenting eccrine squamous syringometaplasia due to pembrolizumab after lenvatinib treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35356259" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7887678" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34596890" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Urea in Dermatology: A Review of its Emollient, Moisturizing, Keratolytic, Skin Barrier Enhancing and Antimicrobial Properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35655045" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355976" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463616" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8102408" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2345070" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625131" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20629022" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22814578" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28715540" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : High dose pyridoxine for the prevention of hand-foot syndrome caused by capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20887495" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23977264" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083217" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29372396" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24656636" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25341548" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28635153" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29682836" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Herbal medicine for hand-foot syndrome induced by fluoropyrimidines: A systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
